Pure Financial Advisors LLC Makes New Investment in Bristol Myers Squibb Company $BMY

Pure Financial Advisors LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 22,483 shares of the biopharmaceutical company’s stock, valued at approximately $1,295,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Northwestern Mutual Investment Management Company LLC grew its stake in Bristol Myers Squibb by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock valued at $3,509,000 after acquiring an additional 172 shares in the last quarter. KCM Investment Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after purchasing an additional 174 shares during the last quarter. Sandy Cove Advisors LLC grew its position in shares of Bristol Myers Squibb by 4.7% during the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 176 shares in the last quarter. Investment Research Partners LLC increased its holdings in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after purchasing an additional 179 shares during the last quarter. Finally, ESG Planning DBA Harper Investing lifted its position in shares of Bristol Myers Squibb by 1.3% in the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 180 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $67.68 on Thursday. The stock has a market cap of $138.25 billion, a price-to-earnings ratio of 14.91, a price-to-earnings-growth ratio of 0.18 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a 50 day moving average price of $61.25 and a 200-day moving average price of $59.60. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the firm posted $1.46 EPS. Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Bank of America dropped their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and set a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Royal Bank Of Canada boosted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Finally, Guggenheim reaffirmed a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.